Long-Term Safety and Effectiveness of Statins for Heart Transplant Recipients in Routine Clinical Practice

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1507-1510

  Grigioni, F ^a   Carigi, S ^a   Potena, L ^a   Fabbri, F ^a   Russo, A ^a   Musuraca, A C ^a   Coccolo, F ^a   Magnani, G ^a   Ortolani, P ^a   Leone, O ^a   Arpesella, G ^a   Magelli, C ^a   Branzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; AZATHIOPRINE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; PREDNISONE; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL PRACTICE; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; LINEAR SYSTEM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYOSITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT DURATION;

ADULT; FEMALE; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT OUTCOME;

EID: 33745197501     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.071     Document Type: Article

References (12)

1. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621
2. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. a four-year randomized trial. Circulation 96 (1997) 1398
3. Rodriguez J.A., Crespo-Leiro M.G., Paniagua M.J., et al. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Transplant Proc 31 (1999) 2522
4. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567
5. Kuo P.C., Kirshenbaum J.M., Gordon J., et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 64 (1989) 631
6. Hidalgo L., Zambrana J.L., Blanco-Molina A., et al. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation. J Heart Lung Transplant 14 (1995) 461
7. Magnani G., Carinci V., Magelli C., et al. Role of statins in the management of dyslipidemia after cardiac transplant. randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 19 (2000) 710
8. Keogh A., Macdonald P., Kaan A., et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 19 (2000) 529
9. Mehra M.R., Uber P.A., Vivekananthan K., et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40 (2002) 1609
10. Gaist D., Rodriguez L.A., Huerta C., et al. Lipid-lowering drugs and risk of myopathy. a population-based follow-up study. Epidemiology 12 (2001) 565
11. Ballantyne C.M., Bourge R.C., Domalik L.J., et al. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 78 (1994) 532
12. Davidson M.H. Does differing metabolism by cytochrome p450 have clinical importance?. Curr Atheroscler Rep 2 (2000) 14